Boan Biologics receives IND approval for Phase II clinical trial of BA1106 in non-small cell lung cancer
Boan Biologics (06955.HK) has received approval from the Center for Drug Evaluation (CDE) for its Investigational New Drug (IND) application for a Phase II clinical trial of BA1106 in combination with BA1104 for non-small cell lung cancer.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.